Skip to main
PCVX
PCVX logo

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc is positioned favorably in the biotechnology sector with its innovative vaccine candidates, notably VAX-24 and VAX-31, demonstrating superior immune responses compared to existing competitors like Prevnar 20. The company has identified significant potential for global revenues exceeding $7-10 billion, supported by upcoming clinical data that may solidify its leadership in next-generation pneumococcal conjugate vaccines. As the company continues to generate encouraging results in both adult and pediatric studies, Vaxcyte reflects a compelling investment opportunity grounded in its strong clinical performance and market potential.

Bears say

The analysis of Vaxcyte Inc indicates a substantial negative outlook primarily due to several inherent risks in their clinical development process. Key concerns include potential delays in R&D, possible underperformance of vaccine efficacy or safety compared to expectations, and lower-than-anticipated commercial uptake, all of which could significantly impact their market position. Additionally, the ongoing uncertainty surrounding anti-vaccine sentiment and competition advancing more rapidly poses further threats to Vaxcyte's future revenue potential, especially if regulatory bodies do not endorse their vaccines as part of national vaccination guidelines.

Vaxcyte (PCVX) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Vaxcyte (PCVX) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.